News und Analysen

If you're looking for dividend stocks that can provide steady income and growth potential, you might want to consider adding Amgen (NASDAQ: AMGN) and American Express (NYSE: AXP) to your portfolio

Finding dividend stocks worth holding onto for good isn't an easy task. Investors shouldn't necessarily rely on a company's current dividend yield to make that decision. Recent history has shown

If you're looking for dividend stocks that offer both attractive yields and strong growth prospects, you might want to consider AbbVie (NYSE: ABBV) and Bristol Myers Squibb (NYSE: BMY). Both of

Despite its formidable market capitalization of $174 billion and more than 100 years in operation, Abbott Laboratories (NYSE: ABT) is a stock that can sometimes be overlooked. It doesn't make

Pharmaceutical giant Johnson & Johnson (NYSE: JNJ) is no stranger to legal issues. The company is still dealing with a barrage of lawsuits alleging that its talc-based products gave customers

We all love a good bargain, whether we're shopping for food, clothing -- or stocks. And even though the stock market has gained this year -- with the S&P 500 rising in the double digits -- there

Healthcare is an evergreen frontier for investing. An endless need for better treatments and cures demands innovation and growth, which isn't a bad place to find long-term winners you can stick in a

With shares of the gene sequencing giant Illumina (NASDAQ: ILMN) collapsing by 53% over the last three years due to a combination of a botched acquisition attempt and weakness in its core business

Not all dividend stocks are created equal. Some haven't slashed their payouts in years and probably won't anytime soon, while others aren't so lucky. One dividend-paying company recently decided to

As you may have heard this summer, Biogen (NASDAQ: BIIB) is taking out a $1.5 billion-dollar loan to fund its acquisition of rare disease drug developer Reata Pharmaceuticals (NASDAQ: RETA) for $7.3

On average, healthcare stocks haven't kept up with the gains made by the rest of the market this year. While the S&P 500 index is up by more than 17% year to date, that sector's stocks are down by

Sometimes, the laws of physics seem to apply to the stock market. That's especially the case when it comes to momentum. When certain stocks get a head of steam going, it's hard to slow them down.

Certain stocks tend to perform better in a bull market, while others show their strengths in bear times. If you add both of these types of stocks to your portfolio, you're likely to benefit over the

If, like many other investors, you've written off big pharma stocks because of their reputation for being slow-growing giants, Vertex Pharmaceuticals (NASDAQ: VRTX) might be the breath of fresh air

September has historically been the worst month for the S&P 500, a phenomenon called the "September effect." The next few weeks may or may not live up (or down) to these low expectations, but

Biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) is firing on all cylinders. The company has performed better than the broader market in the past year as its core cystic fibrosis (CF) franchise

For any investment, getting it to $1 million can be a lofty goal to set. It's by no means an easy task, and will require a sizable buy-in, lots of patience, and good returns along the way. Below

Inflation is making life harder for everyone, including retirees who need to stretch out their savings to help cover additional costs. One way to help offset rising inflation is to invest in

CVS Health (NYSE: CVS) has been selling health and beauty products since 1963. Over those six decades, the pharmacy operator and retailer built up a giant operation that now includes a pharmacy

If you're trying to build a passive income stream to eventually fuel your dream retirement, Abbott Laboratories (NYSE: ABT) is a stock you probably want to know more about. This legendary dividend

Shares of Zai Lab (NASDAQ: ZLAB) were up more than 10% as of 11 a.m. on Tuesday. The Chinese biotech stock rose after the company announced positive phase 3 trial data regarding Tivdak as a

Unlike many of its big pharma peers, Eli Lilly (NYSE: LLY) is a growth stock that's likely to maintain a faster-than-average pace of expansion over the next few years. Between its massive portfolio

Though the pandemic isn't over, people haven't been rushing out to get coronavirus vaccines these days. This spring, the international public health emergency came to an end, and it looked as if we

Many investors are having a hard time finding good reasons to invest in Pfizer (NYSE: PFE) right now, at least if we go by the company's performance in the stock market this year. Pfizer's shares

On Aug. 23, CVS Health (NYSE: CVS) made waves when it announced that it will be launching a new business called Cordavis that will be devoted to commercializing biosimilar medicines. If you aren't